CSPC Innovation Pharmaceutical Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Feng Han

Chief Executive Officer (CEO)

CN¥813.7k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.6yrs
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	1.6yrs

Actualizaciones recientes de la dirección

Recent updates

Are CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Investors Paying Above The Intrinsic Value?

Nov 21

Why CSPC Innovation Pharmaceutical's (SZSE:300765) Shaky Earnings Are Just The Beginning Of Its Problems

Oct 31

Earnings Tell The Story For CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) As Its Stock Soars 27%

Sep 30

Estimating The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)

Aug 16

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) 27% Share Price Plunge Could Signal Some Risk

Jul 04

CSPC Innovation Pharmaceutical's (SZSE:300765) Weak Earnings May Only Reveal A Part Of The Whole Picture

Apr 29

CSPC Innovation Pharmaceutical (SZSE:300765) Will Pay A Larger Dividend Than Last Year At CN¥0.32

Apr 25

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) P/E Still Appears To Be Reasonable

Apr 24

CEO

Feng Han (50 yo)

1.6yrs

Permanencia

CN¥813,700

Compensación

Mr. Feng Han is GM & Director of CSPC Innovation Pharmaceutical Co., Ltd. from April 07, 2023.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Feng Han	GM & Director	1.6yrs	CN¥813.70k	sin datos
Weidong Pan	Chairman	6.9yrs	sin datos	sin datos
Huaiyu Wang	Non-Independent Director	6.9yrs	sin datos	0.0013% CN¥ 490.6k
Lei Cai	Non-Independent Director	1.6yrs	sin datos	sin datos
Dong Yang	Non-Independent Director	1.6yrs	sin datos	sin datos
Bing Yao	Non-Independent Director	1.6yrs	sin datos	sin datos
Dibin Li	Independent Director	1.6yrs	CN¥45.00k	sin datos
Peng Yang	Independent Director	1.6yrs	CN¥45.00k	sin datos
Congzhi Di	Independent Director	1.6yrs	CN¥45.00k	sin datos
Ling Zhang	Non-Employee Supervisor	1.6yrs	sin datos	sin datos
Jiyong Zhang	Non-Employee Supervisor	1.6yrs	sin datos	sin datos
Bing Yuan	Employee Supervisor	4.6yrs	sin datos	sin datos

1.6yrs

Permanencia media

49.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 300765 no se considera experimentada (1.6 años de permanencia promedio), lo que sugiere una nueva junta directiva.

CSPC Innovation Pharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Apr 09, 2024

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Apr 09, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Recent updates

Are CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Investors Paying Above The Intrinsic Value?

Now 24% overvalued after recent price rise

Investor sentiment deteriorates as stock falls 18%

Why CSPC Innovation Pharmaceutical's (SZSE:300765) Shaky Earnings Are Just The Beginning Of Its Problems

Consensus EPS estimates fall by 10%

Third quarter 2024 earnings released: EPS: CN¥0.002 (vs CN¥0.13 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Price target increased by 7.6% to CN¥41.19

Earnings Tell The Story For CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) As Its Stock Soars 27%

CSPC Innovation Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 24%

Now 21% overvalued after recent price rise

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.16 in 2Q 2023)

Estimating The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)

Now 24% overvalued

Now 20% overvalued

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) 27% Share Price Plunge Could Signal Some Risk

Price target increased by 7.0% to CN¥43.00

CSPC Innovation Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024

Consensus EPS estimates fall by 10%

CSPC Innovation Pharmaceutical's (SZSE:300765) Weak Earnings May Only Reveal A Part Of The Whole Picture

CSPC Innovation Pharmaceutical (SZSE:300765) Will Pay A Larger Dividend Than Last Year At CN¥0.32

Dividend of CN¥0.32 announced

First quarter 2024 earnings released: EPS: CN¥0.068 (vs CN¥0.16 in 1Q 2023)

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) P/E Still Appears To Be Reasonable

CSPC Innovation Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Apr 09, 2024

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Apr 09, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 23%

Price target increased by 70% to CN¥49.46

High number of new and inexperienced directors

CSPC Innovation Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 15, 2024

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 34%

Third quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.16 in 3Q 2022)

Investor sentiment improves as stock rises 20%

CSPC Innovation Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) announces an Equity Buyback for CNY 421.8 million worth of its shares.

CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) announces an Equity Buyback for CNY 421.8 million worth of its shares.

Investor sentiment improves as stock rises 17%

Second quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.20 in 2Q 2022)

CSPC Innovation Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Now 21% undervalued

High number of new and inexperienced directors

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.15 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.14 in 2Q 2021)

CSPC Innovation Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding

Investor sentiment improved over the past week

CSPC Innovation Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on June 7, 2022

First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.15 in 1Q 2021)

CSPC Innovation Pharmaceutical Co., Ltd. Approves Cash Dividend (Tax Included) for the Year 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.14 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.20 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.13 in 1Q 2020)

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS CN¥0.71 (vs CN¥0.69 in FY 2019)

New 90-day low: CN¥16.49

CSPC Innovation Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 05, 2021

New 90-day low: CN¥17.89